CoChat
Sign Up
Cited by 24Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsFatty Acid Research and Health

The LipiDiDiet trial: what does it add to the current evidence for Fortasyn Connect in early Alzheimer’s disease?

Open access
Rasmussen, Jill·2019·Clinical Interventions in Aging
DOI 10.2147/cia.s211739PMC PMC6699494
Open this paper in CoChat — free accountOpen PDF

Abstract

Nutritional factors can influence the risk of developing Alzheimer's disease (AD) and its rate of progression, and there is, therefore, increasing interest in nutrition as a modifiable risk factor for the disease. Synaptic loss is an important feature of early AD, and the formation of new synapses is dependent on key nutritional elements that are known to be deficient in patients with AD. The daily medical food, Souvenaid, contains Fortasyn Connect, a multinutrient combination developed to specifically address these deficiencies, comprising docosahexaenoic acid, eicosapentaenoic acid, uridine monophosphate, choline, phospholipids, selenium, folic acid, and vitamins B12, B6, C, and E. Although yielding heterogeneous findings, clinical studies of Fortasyn Connect provide preliminary evidence of clinically relevant benefits on cognitive outcomes in prodromal and early AD. The LipiDiDiet trial investigated the effects of Fortasyn Connect on cognition and related measures in prodromal AD, and is the first randomized, controlled, double-blind, multicenter trial study of a non-pharmacological intervention in this setting. The primary efficacy endpoint was change over 24 months in a composite score of cognitive performance using a neuropsychological test battery. Fortasyn Connect had no significant effect on this endpoint, but demonstrated a significant benefit on secondary endpoints, including domains of cognition affected by AD (attention, memory, executive function) and hippocampal atrophy, suggesting a potential benefit on disease progression. Other studies have demonstrated benefits for Fortasyn Connect on nutritional markers and levels of plasma homocysteine. Taken together, current evidence indicates that Fortasyn Connect may show benefit on domains of cognition affected by AD and nutritional measures that influence risk factors for its progression; that it has greater potential for benefit earlier rather than later in the disease; and that it is safe and well tolerated, alone or in combination with AD medications. Further research into its potential role in AD management is therefore warranted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/cia.s211739

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Research shows a positive correlation between increased physical activity, cognitive training, improved nutrition, and slowing cognitive and functional decline and intensity of BPSD.

    “Indeed, research shows a positive correlation between increased physical activity, cognitive training, improved nutrition, and slowing cognitive and functional decline and intensity of BPSD.”

    From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [172]

    The 'Implications for clinical practice and future research' section describes a trial combining nutritional guidance, exercise, and cognitive training, and reports beneficial cognitive outcomes associated with diet. The 'LipiDiDiet trial > Key findings' section reports less deterioration on a clinical rating scale with a specific multinutrient, but not with that combined lifestyle intervention. The paper does not establish that increased physical activity, cognitive training, and nutrition together slow functional decline or reduce the intensity of BPSD. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 31

  1. [1]Kennedy EP, Weiss SB. The function of cytidine coenzymes in the biosynthesis of phospholipids. J Biol Chem. 1956; 222(1): 193– 214. 13366993
  2. [2]Wurtman RJ, Cansev M, Sakamoto T, Ulus IH. Use of phosphatide precursors to promote synaptogenesis. Annu Rev Nutr. 2009; 29: 59– 87. doi: 10.1146/annurev-nutr-080508-141059 19400698 · DOI
  3. [3]van Wijk N, Broersen LM, de Wilde MC, et al. Targeting synaptic dysfunction in Alzheimer’s disease by administering a specific nutrient combination. J Alzheimer’s Dis. 2014; 38(3): 459– 479. doi: 10.3233/JAD-130998 23985420 · DOI · Paper page
  4. [4]Jicha GA, Markesbery WR. Omega-3 fatty acids: potential role in the management of early Alzheimer’s disease. Clin Interv Aging. 2010; 5: 45– 61. doi: 10.2147/CIA.S5231 20396634 PMC2854051 · DOI
  5. [5]Smach MA, Jacob N, Golmard J-L, et al. Folate and homocysteine in the cerebrospinal fluid of patients with Alzheimer’s disease or dementia: a case control study. Eur Neurol. 2011; 65(5): 270– 278. doi: 10.1159/000326301 21474939 · DOI
  6. [6]Glasø M, Nordbø G, Diep L, Bøhmer T. Reduced concentrations of several vitamins in normal weight patients with late-onset dementia of the Alzheimer type without vascular disease. J Nutr Health Aging. 2004; 8(5): 407– 413. 15359361
  7. [7]Olde Rikkert MG, Verhey FR, Sijben JW, et al. Differences in nutritional status between very mild Alzheimer’s disease patients and healthy controls. J Alzheimers Dis. 2014;(41): 261– 271. doi: 10.3233/JAD-131892 24614903 · DOI
  8. [8]Cohen BM, Renshaw PF, Stoll AL, Wurtman RJ, Yurgelun-Todd D, Babb SM. Decreased brain choline uptake in older adults. An in vivo proton magnetic resonance spectroscopy study. JAMA. 1995; 274(11): 902– 907.doi: 10.1001/jama.1995.03530110064037 7674505 · DOI
  9. [10]Broersen LM, Kuipers AA, Balvers M, et al. A specific multi-nutrient diet reduces alzheimer-like pathology in young adult AbetaPPswe/PS1dE9 mice. J Alzheimers Dis. 2013; 33(1): 177– 190. doi: 10.3233/JAD-2012-112039 22914588 · DOI
  10. [11]Koivisto H, Grimm MO, Rothhaar TL, et al. Special lipid-based diets alleviate cognitive deficits in the APPswe/PS1dE9 transgenic mouse model of Alzheimer’s disease independent of brain amyloid deposition. J Nutr Biochem. 2014; 25(2): 157– 169. doi: 10.1016/j.jnutbio.2013.09.015 24445040 · DOI
  11. [12]Zerbi V, Jansen D, Wiesmann M, et al. Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer’s disease. Neurobiol Aging. 2014; 35(3): 600– 613. doi: 10.1016/j.neurobiolaging.2013.09.038 24210253 · DOI
  12. [13]Holguin S, Martinez J, Chow C, Wurtman R. Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils. FASEB J. 2008; 22(11): 3938– 3946. doi: 10.1096/fj.08-112425 18606862 PMC2574024 · DOI
  13. [14]Jansen D, Zerbi V, Arnoldussen IA, et al. Effects of specific multi-nutrient enriched diets on cerebral metabolism, cognition and neuropathology in AbetaPPswe-PS1dE9 mice. PLoS One. 2013; 8(9): e75393. doi: 10.1371/journal.pone.0075393 24086523 PMC3782450 · DOI
  14. [15]Cansev M, van Wijk N, Turkyilmaz M, Orhan F, Sijben JW, Broersen LM. Specific multi-nutrient enriched diet enhances hippocampal cholinergic transmission in aged rats. Neurobiol Aging. 2015; 36(1): 344– 351. doi: 10.1016/j.neurobiolaging.2014.07.021 25146455 · DOI
  15. [16]Janickova H, Rudajev V, Dolejsi E, et al. Lipid-based diets improve muscarinic neurotransmission in the hippocampus of transgenic APPswe/PS1dE9 Mice. Curr Alzheimer Res. 2015; 12(10): 923– 931. doi: 10.2174/1567205012666151027130350 26502816 · DOI
  16. [17]Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6(8): 734– 746. doi: 10.1016/S1474-4422(07)70178-3 17616482 · DOI · Paper page
  17. [18]Scheltens P, Kamphuis PJ, Verhey FR, et al. Efficacy of a medical food in mild Alzheimer’s disease: a randomized, controlled trial. Alzheimers Dement. 2010; 6(1): 1– 10.e1. doi: 10.1016/j.jalz.2009.10.003 20129316 · DOI
  18. [19]Scheltens P, Twisk JW, Blesa R, et al. Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial. J Alzheimers Dis. 2012; 31(1): 225– 236. doi: 10.3233/JAD-2012-121189 22766770 · DOI
  19. [22]Pardini M, Serrato C, Guida S, et al. Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: a proof-of-concept study. Neurodegener Dis. 2015; 15(1): 58– 62. doi: 10.1159/000369811 25592742 · DOI
  20. [23]de Waal H, Stam CJ, Lansbergen MM, et al. The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer’s disease: a randomised controlled study. PLoS One. 2014; 9(1): e86558. doi: 10.1371/journal.pone.0086558 24475144 PMC3903587 · DOI
  21. [24]Podhorna J, Krahnke T, Shear M, Harrison JE. Alzheimer’s Disease Neuroimaging Initiative. Alzheimer’s Disease Assessment Scale–cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies. Alzheimer’s Res Ther. 2016; 8: 8. doi: 10.1186/s13195-016-0170-5 26868820 PMC4751673 · DOI
  22. [25]Samtani MN, Raghavan N, Novak G, Nandy P, Narayan VA. Disease progression model for Clinical Dementia Rating–Sum of Boxes in mild cognitive impairment and Alzheimer’s subjects from the Alzheimer’s Disease Neuroimaging Initiative. Neuropsychiatr Dis Treat. 2014; 10: 929– 952. doi: 10.2147/NDT.S62323 24926196 PMC4049432 · DOI
  23. [26]Cummings J, Scheltens P, McKeith I, et al. Effect size analyses of Souvenaid in patients with Alzheimer’s disease. J Alzheimers Dis. 2017; 55(3): 1131– 1139. doi: 10.3233/JAD-160745 27767993 PMC5147481 · DOI
  24. [27]Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2004; 75(5): 677– 685. doi: 10.1136/jnnp.2003.029074 15090558 PMC1763555 · DOI
  25. [28]Douaud G, Refsum H, de Jager CA, et al. Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci USA. 2013; 110(23): 9523– 9528. doi: 10.1073/pnas.1301816110 23690582 PMC3677457 · DOI
  26. [29]Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014; 13(6): 614– 629. doi: 10.1016/S1474-4422(14)70090-0 24849862 · DOI · Paper page
  27. [30]Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med. 2002; 346(7): 476– 483. doi: 10.1056/NEJMoa011613 11844848 · DOI · Paper page
  28. [31]Kivipelto M, Solomon A, Ahtiluoto S, et al. The Finnish Geriatric Intervention Study to prevent cognitive impairment and disability (FINGER): study design and progress. Alzheimers Dement. 2013; 9(6): 657– 665. doi: 10.1016/j.jalz.2012.09.012 23332672 · DOI · Paper page
  29. [32]Gillette-Guyonnet S, Andrieu S, Dantoine T, Dartigues JF, Touchon J, Vellas B; MAPT Study Group. Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer’s disease. Alzheimers Dement. 2009; 5(2): 114– 121. doi: 10.1016/j.jalz.2009.01.008 19328438 · DOI
  30. [33]Lehtisalo J, Levälahti E, Lindström J, et al. Dietary changes and cognition over 2 years within a multidomain intervention trial-The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimers Dement. 2019; 15(3): 410– 417. doi: 10.1016/j.jalz.2018.10.001 30527596 · DOI · Paper page
  31. [34]Rosenberg A, Ngandu T, Rusanen M, et al. Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: the FINGER trial. Alzheimers Dement. 2018; 14(3): 263– 270. doi: 10.1016/j.jalz.2017.09.006 29055814 · DOI · Paper page

Cited by

Sorted by citations

Authors
Rasmussen, J.
Affiliations
Royal College of General Practitioners (GB)
Corresponding author
Rasmussen, Jill
ORCID
Rasmussen, Jill
Venue
Clinical Interventions in Aging
Publisher
Informa UK Limited
Published
2019-08
Volume
Volume 14
Pages
1481-1492
ISSN
  • 1176-9092 (ISSN-L)
  • 1178-1998
DOI
10.2147/cia.s211739
PMC
PMC6699494
OpenAlex
W2968482908
Cited by
24
References
3
Citations by year
2026: 3 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 8 · 2021: 6 · 2020: 1
FWCI
2.99
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Interventions in Aging (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Keywords
Souvenaid, early Alzheimer's disease, prodromal Alzheimer's disease, dietary intervention, cognitive function, hippocampal atrophy, homocysteine, docosahexaenoic acid, eicosapentaenoic acid, uridine monophosphate, choline, disease progression, non-pharmacological treatment
MeSH terms
Aged, Alzheimer Disease, Docosahexaenoic Acids, Double-Blind Method, Female, Humans, Male, Neuropsychological Tests, Nutritional Status, Phospholipids, Eicosapentaenoic Acid, Outcome Assessment, Health Care, Disease Progression, Dietary Supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review